Centrum Badan Klinicznych Pi-House Sp. z o.o.

The site is conducting studies that target heart‑related health, especially conditions linked to weight and blood‑sugar control.

• Obesity management with novel weight‑loss agents
• Type 2 diabetes combination therapies to improve glycemic control
• Metabolic dysfunction‑associated steatotic liver disease interventions

With 98 trials and 32 investigators, Centrum Badan Klinicznych Pi‑House in Gdansk is a key hub for cardiovascular research in Europe.

Research focuses on endocrine disorders that affect metabolism and quality of life.

• Type 2 diabetes mellitus adjunctive treatments
• Obesity and overweight interventions
• Hormonal regulation in menstrual migraine

The trials aim to improve hormone‑based therapies and are run by a multidisciplinary team at the Gdansk facility.

Studies evaluate new ways to modulate immune responses in skin and allergic conditions.

• Atopic dermatitis biologic and JAK‑inhibitor trials
• Psoriasis and chronic hand eczema therapies
• Chronic spontaneous urticaria novel antihistamine strategies
• Hidradenitis suppurativa targeted treatments
• Vitiligo regenerative approaches

These immune‑focused trials seek to reduce inflammation and improve skin health for patients across Poland.

The program addresses joint and spine disorders that limit daily activity.

• Rheumatoid arthritis disease‑modifying studies
• Psoriatic arthritis biologic comparisons
• Chronic low back pain non‑opioid analgesic evaluation
• Active psoriatic arthritis outcome measures

By exploring both inflammatory and mechanical causes, the trials aim to restore mobility and reduce pain.

Investigations target neurodegenerative and seizure disorders, seeking disease‑modifying options.

• Alzheimer disease early‑stage therapeutic trials
• Epilepsy refractory focal onset and generalized tonic‑clonic seizures
• Tourette syndrome symptom‑reduction studies
• Mild cognitive impairment progression prevention

The goal is to slow cognitive decline and improve seizure control for affected individuals.

Clinical work explores how diet‑related conditions intersect with metabolic health.

• Obesity pharmacologic and lifestyle combos
• Type 2 diabetes multi‑drug regimens
• Metabolic dysfunction‑associated steatotic liver disease novel agents

These studies aim to reduce disease burden through improved metabolic regulation.

Research includes conditions affecting the upper airway and related immune responses.

• Chronic spontaneous urticaria with ENT manifestations
• Allergic rhinitis adjunct therapies
• Nasal inflammation in obstructive sleep apnoea

The trials aim to improve breathing comfort and reduce inflammation in the head‑neck region.

A broad portfolio targets inflammatory skin disorders and connective‑tissue conditions.

• Atopic dermatitis long‑term safety of emerging biologics
• Psoriasis cream and systemic options
• Hidradenitis suppurativa phase studies
• Alopecia areata hair‑regrowth interventions

By addressing skin barrier function and immune pathways, the research seeks durable remission for patients.

Investigations focus on the biochemical pathways that underlie weight and glucose regulation.

• Energy balance in obesity treatment
• Insulin sensitivity enhancement in type 2 diabetes
• Lipid metabolism modulation in steatotic liver disease

The aim is to translate metabolic insights into effective therapeutic options.

Studies examine how brain circuits influence mood and motivation, testing new psychiatric agents.

• Adjunctive aticaprant for anhedonia in major depressive disorder
• Pimavanserin safety in children with autism spectrum disorder
• Atogepant preventive treatment for menstrual migraine

These trials aim to restore normal behavior patterns and alleviate depressive or anxiety symptoms.

Clinical programs target severe psychiatric conditions with innovative pharmacologic approaches.

• Schizophrenia negative‑symptom modulation
• Treatment‑resistant depression combined with psychological support
• Generalized anxiety disorder acute symptom relief
• Obsessive‑compulsive disorder novel agent evaluation

The goal is to provide effective relief for patients whose symptoms persist despite standard care.